Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Future Oncol
; 20(7): 393-407, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-37850363
Cetuximab is a drug for patients with colorectal cancer or cancer of the head and neck. It is usually administered once a week. However, studies have shown that cetuximab given once every 2 weeks instead has similar clinical benefits and side effects. Based on this evidence, the every 2 weeks dosing schedule has been approved for use in USA and Japan. The every 2 weeks dosing schedule is a convenient alternative to the weekly schedule. It may result in fewer hospital visits, improved patient quality of life, reduced healthcare costs and more flexibility for medical staff. This review summarizes the current evidence and benefits for the every 2 weeks dosing schedule.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Squamous Cell
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: